Hepion Pharmaceuticals is a biotechnology business based in the US. Hepion Pharmaceuticals shares (HEPA) are listed on the NASDAQ and all prices are listed in US Dollars. Hepion Pharmaceuticals employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $5.02 |
|---|---|
| 52-week range | $5.20 - $23.85 |
| 50-day moving average | $8.53 |
| 200-day moving average | $11.36 |
| Wall St. target price | $41.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-12.28 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.02 from 2023-09-22
| 1 week (2023-09-15) | -4.38% |
|---|---|
| 1 month (2023-08-24) | -31.79% |
| 3 months (2023-06-23) | -55.54% |
| 6 months (2023-03-24) | 643.70% |
| 1 year (2022-09-23) | 872.87% |
|---|---|
| 2 years (2021-09-24) | 223.87% |
| 3 years (2020-09-24) | 73.10% |
| 5 years (2018-09-24) | 42.427 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -47.49% |
| Return on equity TTM | -91.14% |
| Profit margin | 0% |
| Book value | $6.43 |
| Market Capitalization | $28.3 million |
TTM: trailing 12 months
We're not expecting Hepion Pharmaceuticals to pay a dividend over the next 12 months.
Hepion Pharmaceuticals's shares were split on a 1:20 basis on 10 May 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Hepion Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Hepion Pharmaceuticals shares which in turn could have impacted Hepion Pharmaceuticals's share price.
Over the last 12 months, Hepion Pharmaceuticals's shares have ranged in value from as little as $5.2 up to $23.854. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hepion Pharmaceuticals's is 1.6962. This would suggest that Hepion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Hepion Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.